Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients with classical complement-mediated disorders of the brain, body, and eye, anno...
Annexon Biosciences (ANNX): Q3 GAAP EPS of -$0.77 misses by $0.43.Cash balance of $370.7M as of Sept. 30, 2020 bolstered by July IPO.Press Release For further details see: Annexon Biosciences EPS misses by $0.43
– Cash balance of $370.7 million as of September 30, 2020 bolstered by July IPO – – Recently expanded ANX005 clinical program into neurodegeneration, with initiation of Phase 2 in Huntington’s Disease – – Fully enrolled Phase 1b DDI trial in Gui...
Annexon (ANNX) has initiated a Phase 2 study of monoclonal antibody ANX005 in Huntington’s Disease ((HD)), a progressive movement disorder. Initial results from the trial expected in 2H of 2021.The 24-subject trial is designed to assess safety, tolerability and biomarkers of targe...
– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb – SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therap...
Gainers: JinkoSolar Holding (JKS) +18%.HireQuest (HQI) +16%.American Well (AMWL) +16%.Hilltop Holdings (HTH) +13%.Daqo New Energy (DQ) +12%.Perion Network (PERI) +12%.Qutoutiao (QTT) +11%.Entercom Communications (ETM) +10%.Aerpio Pharmaceuticals (ARPO) +9%.Annexon (ANNX) +8%.Lo...
Annexon Biosciences (NASDAQ: ANNX ) : Q2 GAAP EPS of -$28.87. More news on: Annexon, Inc., Earnings news and commentary, Read more ...
– Completed $263M IPO in July, and private financing in late June – – Company plans to initiate four new clinical trials by year-end, including in three expanded indications for ANX005 and first-in-human trial of ANX009 – – Phase 2 trials o...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
SOUTH SAN FRANCISCO, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced the appo...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 17:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation BRISBANE, Calif., July 11, 2024 (GLOBE N...
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of Health Over Placebo on GBS-DS by Week 26, Increa...